Zura Bio’s (ZURA) Overweight Rating Reiterated at Cantor Fitzgerald

Zura Bio (NASDAQ:ZURA)‘s stock had its “overweight” rating reiterated by stock analysts at Cantor Fitzgerald in a research note issued to investors on Wednesday,Benzinga reports.

Several other equities research analysts have also weighed in on ZURA. HC Wainwright reiterated a “neutral” rating and issued a $5.00 price objective on shares of Zura Bio in a research note on Monday, November 18th. Piper Sandler reaffirmed an “overweight” rating and set a $26.00 price target on shares of Zura Bio in a report on Thursday, September 19th. Chardan Capital lowered their target price on Zura Bio from $14.00 to $12.00 and set a “buy” rating for the company in a research note on Friday, November 8th. Leerink Partners started coverage on shares of Zura Bio in a research report on Monday, November 4th. They set an “outperform” rating and a $15.00 price target on the stock. Finally, Leerink Partnrs upgraded shares of Zura Bio to a “strong-buy” rating in a research report on Monday, November 4th. One analyst has rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Buy” and an average price target of $15.80.

Zura Bio Trading Down 9.7 %

Shares of NASDAQ:ZURA traded down $0.27 during midday trading on Wednesday, hitting $2.51. The company’s stock had a trading volume of 240,536 shares, compared to its average volume of 330,566. The stock’s 50 day simple moving average is $3.87 and its 200 day simple moving average is $3.84. Zura Bio has a fifty-two week low of $2.00 and a fifty-two week high of $6.35.

Zura Bio (NASDAQ:ZURA) last posted its quarterly earnings results on Thursday, November 7th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by ($0.12). Equities research analysts predict that Zura Bio will post -0.65 earnings per share for the current year.

Insider Transactions at Zura Bio

In related news, Director Parvinder Thiara sold 1,001,633 shares of Zura Bio stock in a transaction on Monday, November 25th. The stock was sold at an average price of $2.73, for a total transaction of $2,734,458.09. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 22.10% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Renaissance Technologies LLC raised its holdings in Zura Bio by 51.3% in the second quarter. Renaissance Technologies LLC now owns 17,400 shares of the company’s stock worth $61,000 after purchasing an additional 5,900 shares during the period. Bank of New York Mellon Corp lifted its holdings in shares of Zura Bio by 15.8% during the 2nd quarter. Bank of New York Mellon Corp now owns 47,109 shares of the company’s stock valued at $165,000 after purchasing an additional 6,412 shares in the last quarter. Forefront Analytics LLC grew its position in shares of Zura Bio by 22.1% in the 2nd quarter. Forefront Analytics LLC now owns 41,569 shares of the company’s stock valued at $145,000 after purchasing an additional 7,531 shares during the period. Healthcare of Ontario Pension Plan Trust Fund bought a new stake in Zura Bio during the 3rd quarter worth approximately $46,000. Finally, AQR Capital Management LLC bought a new position in Zura Bio in the second quarter valued at approximately $43,000. Institutional investors own 61.14% of the company’s stock.

About Zura Bio

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.